Following news last month that a US Food and Drug Administration (FDA) advisory panel had given its backing to a biosimilar version of Swiss pharma giant Roche’s (ROG: SIX) big-selling cancer drug Herceptin (trastuzumab), a separate copycat version has moved closer to market.
During its meeting in July, the agency’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously to recommend approval of a Herceptin biosimilar developed Netherlands-incorporated Mylan (Nasdaq: MYL) and India’s Biocon (BSE: 532523).
Now Roche will note that US biotech Amgen (Nasdaq: AMGN) and Ireland-incorporated drugmaker Allergan (NYSE: AGN) have submitted a Biologics License Application (BLA) to the FDA for ABP 980, a biosimilar candidate referencing the same drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze